CODX — Co-Diagnostics Income Statement
0.000.00%
Last trade - 00:00- $18.54m
- $10.31m
- $0.62m
Annual income statement for Co-Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 97.9 | 34.2 | 6.81 | 3.92 | 0.622 |
| Cost of Revenue | |||||
| Gross Profit | 86.3 | 28.7 | 2.63 | 2.92 | 0.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 51.8 | 53.3 | 48.4 | 43.3 | 50 |
| Operating Profit | 46.1 | -19.1 | -41.6 | -39.4 | -49.4 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 45.6 | -18.8 | -38.1 | -37.6 | -48.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 36.7 | -14.2 | -35.3 | -37.6 | -47.8 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 36.7 | -14.2 | -35.3 | -37.6 | -46.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 36.7 | -14.2 | -35.3 | -37.6 | -46.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 36.9 | -8.85 | -36.8 | -37.7 | -27 |